8-K: Seres Therapeutics Announces Second Quarter 2024 Results and Strategic Shift with VOWST Asset Sale

Seres Therapeutics reported its Q2 2024 financial results, highlighted by a strategic sale of its VOWST business to Nestle, which is expected to provide a significant cash infusion and extend the company's operational runway.

Summary

• Seres Therapeutics announced its second quarter 2024 financial results, reporting a net loss of $32.9 million, compared to a net income of $46.6 million for the same period in 2023, primarily due to a $125 million milestone payment received in 2023.
• The company's research and development expenses decreased to $17.9 million from $46.8 million year-over-year, due to VOWST manufacturing costs being capitalized and lower personnel costs.
• General and administrative expenses also decreased to $16.1 million from $28.1 million year-over-year, driven by reduced professional fees and personnel costs.
• Second quarter 2024 net sales for VOWST were approximately $14.4 million, a 43% increase compared to the first quarter net sales of $10.1 million.
• Seres' share of the VOWST net loss for the second quarter was $6.6 million.
• The company had $71.2 million in cash and cash equivalents as of June 30, 2024.
• Seres has entered into an agreement to sell its VOWST business to Nestle for a total consideration of up to $525 million, including an upfront payment of $175 million less approximately $20 million in net obligations, a $75 million payment in 2025, and up to $275 million in potential future milestone payments.
• The VOWST asset sale is expected to close within 90 days of the August 6, 2024 agreement signing, subject to stockholder approval and other customary conditions.
• The company expects to use the proceeds from the VOWST sale to retire its debt and fund operations into the fourth quarter of 2025.
• Seres' lead program, SER-155, is on track for a clinical data readout from the placebo-controlled study Cohort 2 in September 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the strategic sale of VOWST, which provides a significant cash infusion and extends the company's runway. However, the company reported a net loss for the quarter and faces risks related to clinical development and future funding.

Positives

• The sale of the VOWST business provides a significant cash infusion of $175 million less approximately $20 million in net obligations at closing, strengthening the balance sheet.
• The transaction is expected to extend the company's operational runway into the fourth quarter of 2025.
• The company plans to retire its senior secured debt facility with the proceeds from the VOWST sale.
• VOWST sales increased by 43% in the second quarter of 2024 compared to the first quarter.
• The SER-155 program remains on track for a clinical data readout in September 2024.
• The company is streamlining operations and reducing its cash burn rate.
• Seres has a validated platform with the successful development and approval of VOWST.

Negatives

• Seres reported a net loss of $32.9 million for the second quarter of 2024, compared to a net income of $46.6 million for the same period in 2023.
• Seres' share of the VOWST net loss for the second quarter was $6.6 million.
• The company is reliant on the VOWST asset sale to extend its cash runway.
• The company will share 50/50 in the profits or losses of the VOWST business through the fourth quarter of 2025.
• The company has a history of operating losses and may never become profitable.

Risks

• The VOWST asset sale is subject to stockholder approval and other customary closing conditions, and may not be completed.
• The company may not receive all future milestone payments related to the VOWST sale.
• The company is reliant on third parties to conduct clinical trials and manufacture product candidates.
• The company faces competition in the biotherapeutics market.
• The company may not be able to protect its intellectual property.
• The company may not be able to retain key personnel or manage its growth.
• The company has incurred significant losses and may never become profitable.
• The company needs additional funding to continue operations.
• The company's novel approach to therapeutic intervention carries inherent risks.
• The 50/50 profit and loss sharing arrangement with Nestle introduces uncertainty in reported results and liquidity.

Future Outlook

Seres expects to use the proceeds from the VOWST asset sale to retire its debt and fund operations into the fourth quarter of 2025, while focusing on the development of its wholly-owned cultivated live biotherapeutic pipeline, including SER-155 and SER-147. The company anticipates a clinical data readout for SER-155 in September 2024 and IND readiness for SER-147 in the second half of 2025.

Management Comments

• Eric Shaff, President and Chief Executive Officer of Seres, stated that the VOWST asset sale will significantly strengthen Seres' balance sheet and advance the company's goal to improve patient outcomes.
• Mr. Shaff also mentioned that the SER-155 program remains on track for a clinical data readout in September, highlighting the potential clinical value and commercial opportunities of the program.

Industry Context

This announcement reflects a strategic shift for Seres, moving away from commercializing VOWST and focusing on its pipeline of wholly-owned cultivated live biotherapeutics. The sale of VOWST to Nestle, a major player in the health and nutrition space, highlights the value of microbiome-based therapies. The focus on SER-155 and SER-147 aligns with the growing interest in using microbiome therapeutics to address serious infections in vulnerable patient populations.

Comparison to Industry Standards

• The 43% increase in VOWST sales quarter-over-quarter indicates a growing market acceptance of microbiome therapeutics for recurrent C. difficile infection, although the company still reported a loss on the product.
• The strategic decision to sell VOWST and focus on pipeline development is similar to other biotech companies that prioritize research and development over commercialization of a single product.
• The focus on preventing infections in vulnerable populations with SER-155 and SER-147 aligns with the industry trend of developing targeted therapies for specific patient groups.
• The company's approach of using cultivated live biotherapeutics is a novel approach compared to traditional pharmaceutical development, but is in line with other companies exploring microbiome-based therapies.
• The company's cash runway extension to Q4 2025 is a positive development, but the company will need to continue to raise capital to fund its pipeline development.

Related Party Transactions

• The document mentions collaboration revenue and profit/loss sharing with Nestl Health Science as related party transactions.
• The VOWST asset sale to SPN, a wholly-owned subsidiary of Nestle, is a related party transaction.

Stakeholder Impact

• Shareholders will need to approve the VOWST asset sale.
• Employees will be impacted by the VOWST asset sale, with more than a third expected to transfer to Nestle Health Science.
• Customers of VOWST will see a change in ownership and management of the product.
• Suppliers will be impacted by the transition of VOWST manufacturing to Nestle Health Science.
• Creditors will be impacted by the retirement of the senior secured debt facility.

Next Steps

• Seres will seek stockholder approval for the VOWST asset sale.
• The company expects to close the VOWST asset sale within 90 days of the August 6, 2024 agreement signing.
• Seres will provide transition services for the VOWST business through the first quarter of 2025.
• The company will provide manufacturing support for VOWST through the end of 2025.
• Seres anticipates a clinical data readout for SER-155 Phase 1b Cohort 2 in September 2024.
• The company plans to evaluate SER-155 and other candidates in additional medically vulnerable patient populations.
• Seres anticipates IND readiness for SER-147 in the second half of 2025.
• The company will engage regulators to assess the path forward for SER-155.

Key Dates

Keywords

Seres Therapeutics, VOWST, Microbiome Therapeutics, Live Biotherapeutics, SER-155, SER-147, Nestle, Asset Sale, Clinical Trials, Infections, GvHD, Allo-HSCT, Financial Results, Cash Runway